Optimizing the Treatment of Invasive Candidiasis-A Case for Combination Therapy

Area of Science:

• Medical Mycology
• Infectious Diseases
• Pharmacology

Background:

• Invasive candidiasis presents a growing global health challenge with high mortality and limited treatments.
• Antifungal resistance is rapidly increasing, with multidrug-resistant species posing a serious threat.
• Antifungal monotherapy may contribute to the development of drug resistance.

Purpose of the Study:

• To examine the role of antifungal monotherapy in driving resistance.
• To explore the potential of combination therapy in preventing antifungal resistance and improving treatment outcomes.
• To evaluate the synergistic activity of antifungal combinations against Candida species.

Main Methods:

• Review of existing laboratory-based evidence on antifungal combination therapy.
• Analysis of the mechanisms by which combination therapy may mitigate resistance.
• Consideration of clinical trial designs incorporating resistance end points.

Main Results:

• Laboratory evidence suggests antifungal combinations can exhibit synergistic activity against Candida species.
• Combination therapy may prevent stress adaptation and the emergence of drug resistance.
• Potential benefits include improved drug penetration, faster fungal clearance, and reduced toxicity.

Conclusions:

• Antifungal combination therapy is a promising strategy to combat invasive candidiasis and emerging resistance.
• Further clinical trials are imperative to validate the efficacy and safety of these combinations.
• Incorporating resistance end points in trials is crucial for assessing treatment success.